The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 335:886-888 September 19, 1996 Number 12
NextNext

Inhaled ß2-Agonists in the Treatment of Asthma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
The introduction of selective, potent inhaled {beta}2-agonists more than 30 years ago revolutionized the treatment of asthma. Until that time, nonselective sympathomimetic agents, such as ephedrine and epinephrine, which stimulate both {alpha}- and {beta}-adrenergic receptors and have a very short duration of action, were used to relieve bronchoconstriction. The selective inhaled {beta}2-agonists, such as terbutaline and albuterol, have a longer duration of action (four to six hours), are potent bronchodilators, relieve symptoms rapidly, and protect against the acute bronchoconstriction caused by stimuli such as exercise1 or the inhalation of cold, dry air.2 For these reasons, in most countries inhaled {beta}2-agonists . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.